<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33333804</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>17</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>12</Issue><PubDate><Year>2020</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>Pathogenic Genome Signatures That Damage Motor Neurons in Amyotrophic Lateral Sclerosis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2687</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells9122687</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is the most frequent motor neuron disease and a neurodegenerative disorder, affecting the upper and/or lower motor neurons. Notably, it invariably leads to death within a few years of onset. Although most ALS cases are sporadic, familial amyotrophic lateral sclerosis (fALS) forms 10% of the cases. In 1993, the first causative gene (<i>SOD1</i>) of fALS was identified. With rapid advances in genetics, over fifty potentially causative or disease-modifying genes have been found in ALS so far. Accordingly, routine diagnostic tests should encompass the oldest and most frequently mutated ALS genes as well as several new important genetic variants in ALS. Herein, we discuss current literatures on the four newly identified ALS-associated genes (<i>CYLD</i>, <i>S1R</i>, <i>GLT8D1</i>, and <i>KIF5A</i>) and the previously well-known ALS genes including <i>SOD1</i>, <i>TARDBP</i>, <i>FUS</i>, and <i>C9orf72</i>. Moreover, we review the pathogenic implications and disease mechanisms of these genes. Elucidation of the cellular and molecular functions of the mutated genes will bring substantial insights for the development of therapeutic approaches to treat ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yousefian-Jazi</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Neuroscience, Brain Science Institute, Korea Institute of Science and Technology, Seoul 02792, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seol</LastName><ForeName>YunHee</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Center for Neuroscience, Brain Science Institute, Korea Institute of Science and Technology, Seoul 02792, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jieun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Neuroscience, Brain Science Institute, Korea Institute of Science and Technology, Seoul 02792, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryu</LastName><ForeName>Hannah L</ForeName><Initials>HL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Boston University Alzheimer's Disease Center, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Junghee</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Boston University Alzheimer's Disease Center, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VA Boston Healthcare System, Boston, MA 02130, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryu</LastName><ForeName>Hoon</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-6544-3732</Identifier><AffiliationInfo><Affiliation>Center for Neuroscience, Brain Science Institute, Korea Institute of Science and Technology, Seoul 02792, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Boston University Alzheimer's Disease Center, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS109537</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034156</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015894" MajorTopicYN="Y">Genome, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">cell damage</Keyword><Keyword MajorTopicYN="N">genome signature</Keyword><Keyword MajorTopicYN="N">motor neuron</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>18</Day><Hour>1</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33333804</ArticleId><ArticleId IdType="pmc">PMC7765192</ArticleId><ArticleId IdType="doi">10.3390/cells9122687</ArticleId><ArticleId IdType="pii">cells9122687</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rowland L.P., Shneider N.A. Amyotrophic lateral sclerosis. N. Engl. J. Med. 2001;344:1688&#x2013;1700. doi: 10.1056/NEJM200105313442207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200105313442207</ArticleId><ArticleId IdType="pubmed">11386269</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A., Logroscino G., Hardiman O., Swingler R., Mitchell D., Beghi E., Traynor B.G. Prognostic factors in ALS: A critical review. Amyotroph. Lateral Scler. 2009;10:310&#x2013;323. doi: 10.3109/17482960802566824.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960802566824</ArticleId><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es M.A., Hardiman O., Chio A., Al-Chalabi A., Pasterkamp R.J., Veldink J.H., van den Berg L.H. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084&#x2013;2098. doi: 10.1016/S0140-6736(17)31287-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov D., Mansfield C., Moussy A., Hermine O. ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment? Front. Aging Neurosci. 2017;9:68. doi: 10.3389/fnagi.2017.00068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00068</ArticleId><ArticleId IdType="pmc">PMC5360725</ArticleId><ArticleId IdType="pubmed">28382000</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O., Al-Chalabi A., Chio A., Corr E.M., Logroscino G., Robberecht W., Shaw P.J., Simmons Z., van den Berg L.H. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Primers. 2017;3:17071. doi: 10.1038/nrdp.2017.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsultan A.A., Waller R., Heath P.R., Kirby J. The genetics of amyotrophic lateral sclerosis: Current insights. Degener. Neurol. Neuromuscul. Dis. 2016;6:49&#x2013;64. doi: 10.2147/dnnd.S84956.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/dnnd.S84956</ArticleId><ArticleId IdType="pmc">PMC6053097</ArticleId><ArticleId IdType="pubmed">30050368</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S., Sayana P., Zhang X., Le W. Genetics of amyotrophic lateral sclerosis: An update. Mol. Neurodegener. 2013;8:28. doi: 10.1186/1750-1326-8-28.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-8-28</ArticleId><ArticleId IdType="pmc">PMC3766231</ArticleId><ArticleId IdType="pubmed">23941283</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacoangeli A., Lin T., Al Khleifat A., Jones A.R., Opie-Martin S., Coleman J.R.I., Shatunov A., Sproviero W., Williams K.L., Garton F., et al. Genome-wide Meta-analysis Finds the ACSL5-ZDHHC6 Locus Is Associated with ALS and Links Weight Loss to the Disease Genetics. Cell Rep. 2020;33:108323. doi: 10.1016/j.celrep.2020.108323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.108323</ArticleId><ArticleId IdType="pmc">PMC7610013</ArticleId><ArticleId IdType="pubmed">33113361</ArticleId></ArticleIdList></Reference><Reference><Citation>Shatunov A., Al-Chalabi A. The genetic architecture of ALS. Neurobiol. Dis. 2021;147:105156. doi: 10.1016/j.nbd.2020.105156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.105156</ArticleId><ArticleId IdType="pubmed">33130222</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R., Flynn L.L., Pitout I.L., Fletcher S., Wilton S.D., Akkari P.A. ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? Front. Neurosci. 2019;13:1310. doi: 10.3389/fnins.2019.01310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan S., Orrell R.W. Pathogenesis of amyotrophic lateral sclerosis. Br. Med. Bull. 2016;119:87&#x2013;98. doi: 10.1093/bmb/ldw026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bmb/ldw026</ArticleId><ArticleId IdType="pubmed">27450455</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner D., Yilmaz R., M&#xfc;ller K., Grehl T., Petri S., Meyer T., Grosskreutz J., Weydt P., Ruf W., Neuwirth C., et al. Hot-spot KIF5A mutations cause familial ALS. Brain. 2018;141:688&#x2013;697. doi: 10.1093/brain/awx370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx370</ArticleId><ArticleId IdType="pmc">PMC5837483</ArticleId><ArticleId IdType="pubmed">29342275</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas A., Kenna K.P., Renton A.E., Ticozzi N., Faghri F., Chia R., Dominov J.A., Kenna B.J., Nalls M.A., Keagle P., et al. Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron. 2018;97:1268&#x2013;1283.e1266. doi: 10.1016/j.neuron.2018.02.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.02.027</ArticleId><ArticleId IdType="pmc">PMC5867896</ArticleId><ArticleId IdType="pubmed">29566793</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J., Moll T., Ramesh T., Castelli L., Beer A., Robins H., Fox I., Niedermoser I., Van Damme P., Moisse M., et al. Mutations in the Glycosyltransferase Domain of GLT8D1 Are Associated with Familial Amyotrophic Lateral Sclerosis. Cell Rep. 2019;26:2298&#x2013;2306.e2295. doi: 10.1016/j.celrep.2019.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2019.02.006</ArticleId><ArticleId IdType="pmc">PMC7003067</ArticleId><ArticleId IdType="pubmed">30811981</ArticleId></ArticleIdList></Reference><Reference><Citation>Couly S., Khalil B., Viguier V., Roussel J., Maurice T., Li&#xe9;vens J.-C. Sigma-1 receptor is a key genetic modulator in amyotrophic lateral sclerosis. Hum. Mol. Genet. 2019;29:529&#x2013;540. doi: 10.1093/hmg/ddz267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddz267</ArticleId><ArticleId IdType="pubmed">31696229</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobson-Stone C., Hallupp M., Shahheydari H., Ragagnin A.M.G., Chatterton Z., Carew-Jones F., Shepherd C.E., Stefen H., Paric E., Fath T., et al. CYLD is a causative gene for frontotemporal dementia&#x2014;Amyotrophic lateral sclerosis. Brain. 2020;143:783&#x2013;799. doi: 10.1093/brain/awaa039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa039</ArticleId><ArticleId IdType="pmc">PMC7089666</ArticleId><ArticleId IdType="pubmed">32185393</ArticleId></ArticleIdList></Reference><Reference><Citation>Farhan S.M.K., Howrigan D.P., Abbott L.E., Klim J.R., Topp S.D., Byrnes A.E., Churchhouse C., Phatnani H., Smith B.N., Rampersaud E., et al. Exome sequencing in amyotrophic lateral sclerosis implicates a novel gene, DNAJC7, encoding a heat-shock protein. Nat. Neurosci. 2019;22:1966&#x2013;1974. doi: 10.1038/s41593-019-0530-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0530-0</ArticleId><ArticleId IdType="pmc">PMC6919277</ArticleId><ArticleId IdType="pubmed">31768050</ArticleId></ArticleIdList></Reference><Reference><Citation>Course M.M., Gudsnuk K., Smukowski S.N., Winston K., Desai N., Ross J.P., Sulovari A., Bourassa C.V., Spiegelman D., Couthouis J., et al. Evolution of a Human-Specific Tandem Repeat Associated with ALS. Am. J. Hum. Genet. 2020;107:445&#x2013;460. doi: 10.1016/j.ajhg.2020.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2020.07.004</ArticleId><ArticleId IdType="pmc">PMC7477013</ArticleId><ArticleId IdType="pubmed">32750315</ArticleId></ArticleIdList></Reference><Reference><Citation>Tazelaar G.H.P., Boeynaems S., De Decker M., van Vugt J.J.F.A., Kool L., Goedee H.S., McLaughlin R.L., Sproviero W., Iacoangeli A., Moisse M., et al. ATXN1 repeat expansions confer risk for amyotrophic lateral sclerosis and contribute to TDP-43 mislocalization. Brain Commun. 2020;2 doi: 10.1093/braincomms/fcaa064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcaa064</ArticleId><ArticleId IdType="pmc">PMC7425293</ArticleId><ArticleId IdType="pubmed">32954321</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura R., Misawa K., Tohnai G., Nakatochi M., Furuhashi S., Atsuta N., Hayashi N., Yokoi D., Watanabe H., Watanabe H., et al. A multi-ethnic meta-analysis identifies novel genes, including ACSL5, associated with amyotrophic lateral sclerosis. Commun. Biol. 2020;3:526. doi: 10.1038/s42003-020-01251-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-020-01251-2</ArticleId><ArticleId IdType="pmc">PMC7511394</ArticleId><ArticleId IdType="pubmed">32968195</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama H., Morino H., Ito H., Izumi Y., Kato H., Watanabe Y., Kinoshita Y., Kamada M., Nodera H., Suzuki H., et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature. 2010;465:223&#x2013;226. doi: 10.1038/nature08971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature08971</ArticleId><ArticleId IdType="pubmed">20428114</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M.R., Hardiman O., Benatar M., Brooks B.R., Chio A., de Carvalho M., Ince P.G., Lin C., Miller R.G., Mitsumoto H., et al. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol. 2013;12:310&#x2013;322. doi: 10.1016/S1474-4422(13)70036-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70036-X</ArticleId><ArticleId IdType="pmc">PMC4565161</ArticleId><ArticleId IdType="pubmed">23415570</ArticleId></ArticleIdList></Reference><Reference><Citation>Haukedal H., Freude K. Implications of Microglia in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. J. Mol. Biol. 2019;431:1818&#x2013;1829. doi: 10.1016/j.jmb.2019.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2019.02.004</ArticleId><ArticleId IdType="pubmed">30763568</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou Z.Y., Zhou Z.R., Che C.H., Liu C.Y., He R.L., Huang H.P. Genetic epidemiology of amyotrophic lateral sclerosis: A systematic review and meta-analysis. J. Neurol Neurosurg. Psychiatry. 2017;88:540&#x2013;549. doi: 10.1136/jnnp-2016-315018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-315018</ArticleId><ArticleId IdType="pubmed">28057713</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirulli E.T., Lasseigne B.N., Petrovski S., Sapp P.C., Dion P.A., Leblond C.S., Couthouis J., Lu Y.-F., Wang Q., Krueger B.J., et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science. 2015;347:1436. doi: 10.1126/science.aaa3650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa3650</ArticleId><ArticleId IdType="pmc">PMC4437632</ArticleId><ArticleId IdType="pubmed">25700176</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J., Blair I.P., Tripathi V.B., Hu X., Vance C., Rogelj B., Ackerley S., Durnall J.C., Williams K.L., Buratti E., et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668&#x2013;1672. doi: 10.1126/science.1154584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1154584</ArticleId><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Orlacchio A., Babalini C., Borreca A., Patrono C., Massa R., Basaran S., Munhoz R.P., Rogaeva E.A., St George-Hyslop P.H., Bernardi G., et al. SPATACSIN mutations cause autosomal recessive juvenile amyotrophic lateral sclerosis. Brain. 2010;133:591&#x2013;598. doi: 10.1093/brain/awp325.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awp325</ArticleId><ArticleId IdType="pmc">PMC2822627</ArticleId><ArticleId IdType="pubmed">20110243</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson J.O., Mandrioli J., Benatar M., Abramzon Y., Van Deerlin V.M., Trojanowski J.Q., Gibbs J.R., Brunetti M., Gronka S., Wuu J., et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron. 2010;68:857&#x2013;864. doi: 10.1016/j.neuron.2010.11.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2010.11.036</ArticleId><ArticleId IdType="pmc">PMC3032425</ArticleId><ArticleId IdType="pubmed">21145000</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H.J., Kim N.C., Wang Y.-D., Scarborough E.A., Moore J., Diaz Z., MacLea K.S., Freibaum B., Li S., Molliex A., et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature. 2013;495:467&#x2013;473. doi: 10.1038/nature11922.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11922</ArticleId><ArticleId IdType="pmc">PMC3756911</ArticleId><ArticleId IdType="pubmed">23455423</ArticleId></ArticleIdList></Reference><Reference><Citation>Elden A.C., Kim H.-J., Hart M.P., Chen-Plotkin A.S., Johnson B.S., Fang X., Armakola M., Geser F., Greene R., Lu M.M., et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466:1069&#x2013;1075. doi: 10.1038/nature09320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09320</ArticleId><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenway M.J., Andersen P.M., Russ C., Ennis S., Cashman S., Donaghy C., Patterson V., Swingler R., Kieran D., Prehn J., et al. ANG mutations segregate with familial and &#x2019;sporadic&#x2019; amyotrophic lateral sclerosis. Nat. Genet. 2006;38:411&#x2013;413. doi: 10.1038/ng1742.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1742</ArticleId><ArticleId IdType="pubmed">16501576</ArticleId></ArticleIdList></Reference><Reference><Citation>Project MinE ALS Sequencing Consortium CHCHD10 variants in amyotrophic lateral sclerosis: Where is the evidence? Ann. Neurol. 2018;84:110&#x2013;116. doi: 10.1002/ana.25273.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25273</ArticleId><ArticleId IdType="pmc">PMC6553489</ArticleId><ArticleId IdType="pubmed">30014597</ArticleId></ArticleIdList></Reference><Reference><Citation>Luty A.A., Kwok J.B.J., Dobson-Stone C., Loy C.T., Coupland K.G., Karlstr&#xf6;m H., Sobow T., Tchorzewska J., Maruszak A., Barcikowska M., et al. Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration&#x2013;motor neuron disease. Ann. Neurol. 2010;68:639&#x2013;649. doi: 10.1002/ana.22274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22274</ArticleId><ArticleId IdType="pubmed">21031579</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Saif A., Al-Mohanna F., Bohlega S. A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis. Ann. Neurol. 2011;70:913&#x2013;919. doi: 10.1002/ana.22534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22534</ArticleId><ArticleId IdType="pubmed">21842496</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow C.Y., Landers J.E., Bergren S.K., Sapp P.C., Grant A.E., Jones J.M., Everett L., Lenk G.M., McKenna-Yasek D.M., Weisman L.S., et al. Deleterious Variants of FIG4, a Phosphoinositide Phosphatase, in Patients with ALS. Am. J. Hum. Genet. 2009;84:85&#x2013;88. doi: 10.1016/j.ajhg.2008.12.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2008.12.010</ArticleId><ArticleId IdType="pmc">PMC2668033</ArticleId><ArticleId IdType="pubmed">19118816</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y.-Z., Bennett C.L., Huynh H.M., Blair I.P., Puls I., Irobi J., Dierick I., Abel A., Kennerson M.L., Rabin B.A., et al. DNA/RNA Helicase Gene Mutations in a Form of Juvenile Amyotrophic Lateral Sclerosis (ALS4) Am. J. Hum. Genet. 2004;74:1128&#x2013;1135. doi: 10.1086/421054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/421054</ArticleId><ArticleId IdType="pmc">PMC1182077</ArticleId><ArticleId IdType="pubmed">15106121</ArticleId></ArticleIdList></Reference><Reference><Citation>Fecto F., Yan J., Vemula S.P., Liu E., Yang Y., Chen W., Zheng J.G., Shi Y., Siddique N., Arrat H., et al. SQSTM1 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis. Arch. Neurol. 2011;68:1440&#x2013;1446. doi: 10.1001/archneurol.2011.250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2011.250</ArticleId><ArticleId IdType="pubmed">22084127</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A., Wieland T., Richter B., Ruf W., Schaeffer V., M&#xfc;ller K., Marroquin N., Nordin F., H&#xfc;bers A., Weydt P., et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat. Neurosci. 2015;18:631&#x2013;636. doi: 10.1038/nn.4000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4000</ArticleId><ArticleId IdType="pubmed">25803835</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenna K.P., van Doormaal P.T.C., Dekker A.M., Ticozzi N., Kenna B.J., Diekstra F.P., van Rheenen W., van Eijk K.R., Jones A.R., Keagle P., et al. NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nat. Genet. 2016;48:1037&#x2013;1042. doi: 10.1038/ng.3626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3626</ArticleId><ArticleId IdType="pmc">PMC5560030</ArticleId><ArticleId IdType="pubmed">27455347</ArticleId></ArticleIdList></Reference><Reference><Citation>Ticozzi N., Vance C., Leclerc A.L., Keagle P., Glass J.D., McKenna-Yasek D., Sapp P.C., Silani V., Bosco D.A., Shaw C.E., et al. Mutational analysis reveals the FUS homolog TAF15 as a candidate gene for familial amyotrophic lateral sclerosis. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2011;156b:285&#x2013;290. doi: 10.1002/ajmg.b.31158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajmg.b.31158</ArticleId><ArticleId IdType="pubmed">21438137</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski T.J., Jr., Bosco D.A., Leclerc A.L., Tamrazian E., Vanderburg C.R., Russ C., Davis A., Gilchrist J., Kasarskis E.J., Munsat T., et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323:1205&#x2013;1208. doi: 10.1126/science.1166066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1166066</ArticleId><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadano S., Hand C.K., Osuga H., Yanagisawa Y., Otomo A., Devon R.S., Miyamoto N., Showguchi-Miyata J., Okada Y., Singaraja R., et al. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat. Genet. 2001;29:166&#x2013;173. doi: 10.1038/ng1001-166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1001-166</ArticleId><ArticleId IdType="pubmed">11586298</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura A.L., Mitne-Neto M., Silva H.C.A., Richieri-Costa A., Middleton S., Cascio D., Kok F., Oliveira J.R.M., Gillingwater T., Webb J., et al. A Mutation in the Vesicle-Trafficking Protein VAPB Causes Late-Onset Spinal Muscular Atrophy and Amyotrophic Lateral Sclerosis. Am. J. Hum. Genet. 2004;75:822&#x2013;831. doi: 10.1086/425287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/425287</ArticleId><ArticleId IdType="pmc">PMC1182111</ArticleId><ArticleId IdType="pubmed">15372378</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A., Andersen P.M., Nilsson P., Chioza B., Andersson J.L., Russ C., Shaw C.E., Powell J.F., Nigel Leigh P. Deletions of the Heavy Neurofilament Subunit Tail in Amyotrophic Lateral Sclerosis. Hum. Mol. Genet. 1999;8:157&#x2013;164. doi: 10.1093/hmg/8.2.157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/8.2.157</ArticleId><ArticleId IdType="pubmed">9931323</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M., Mackenzie I.R., Boeve B.F., Boxer A.L., Baker M., Rutherford N.J., Nicholson A.M., Finch N.A., Flynn H., Adamson J., et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;256. doi: 10.1016/j.neuron.2011.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkinson N., Ince P.G., Smith M.O., Highley R., Skibinski G., Andersen P.M., Morrison K.E., Pall H.S., Hardiman O., Collinge J., et al. ALS phenotypes with mutations in CHMP2B (charged multivesicular body protein 2B) Neurology. 2006;67:1074&#x2013;1077. doi: 10.1212/01.wnl.0000231510.89311.8b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000231510.89311.8b</ArticleId><ArticleId IdType="pubmed">16807408</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson J.O., Pioro E.P., Boehringer A., Chia R., Feit H., Renton A.E., Pliner H.A., Abramzon Y., Marangi G., Winborn B.J., et al. Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. Nat. Neurosci. 2014;17:664&#x2013;666. doi: 10.1038/nn.3688.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3688</ArticleId><ArticleId IdType="pmc">PMC4000579</ArticleId><ArticleId IdType="pubmed">24686783</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C.-H., Fallini C., Ticozzi N., Keagle P.J., Sapp P.C., Piotrowska K., Lowe P., Koppers M., McKenna-Yasek D., Baron D.M., et al. Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature. 2012;488:499&#x2013;503. doi: 10.1038/nature11280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11280</ArticleId><ArticleId IdType="pmc">PMC3575525</ArticleId><ArticleId IdType="pubmed">22801503</ArticleId></ArticleIdList></Reference><Reference><Citation>Gros-Louis F., Larivi&#xe8;re R., Gowing G., Laurent S., Camu W., Bouchard J.P., Meininger V., Rouleau G.A., Julien J.P. A frameshift deletion in peripherin gene associated with amyotrophic lateral sclerosis. J. Biol. Chem. 2004;279:45951&#x2013;45956. doi: 10.1074/jbc.M408139200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M408139200</ArticleId><ArticleId IdType="pubmed">15322088</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith B.N., Ticozzi N., Fallini C., Gkazi A.S., Topp S., Kenna K.P., Scotter E.L., Kost J., Keagle P., Miller J.W., et al. Exome-wide Rare Variant Analysis Identifies TUBA4A Mutations Associated with Familial ALS. Neuron. 2014;84:324&#x2013;331. doi: 10.1016/j.neuron.2014.09.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.09.027</ArticleId><ArticleId IdType="pmc">PMC4521390</ArticleId><ArticleId IdType="pubmed">25374358</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson C.L., Lemmens R., Miskiewicz K., Broom W.J., Hansen V.K., van Vught P.W.J., Landers J.E., Sapp P., Van Den Bosch L., Knight J., et al. Variants of the elongator protein 3 ( ELP3 ) gene are associated with motor neuron degeneration. Hum. Mol. Genet. 2008;18:472&#x2013;481. doi: 10.1093/hmg/ddn375.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddn375</ArticleId><ArticleId IdType="pmc">PMC2638803</ArticleId><ArticleId IdType="pubmed">18996918</ArticleId></ArticleIdList></Reference><Reference><Citation>Puls I., Jonnakuty C., LaMonte B.H., Holzbaur E.L.F., Tokito M., Mann E., Floeter M.K., Bidus K., Drayna D., Oh S.J., et al. Mutant dynactin in motor neuron disease. Nat. Genet. 2003;33:455&#x2013;456. doi: 10.1038/ng1123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1123</ArticleId><ArticleId IdType="pubmed">12627231</ArticleId></ArticleIdList></Reference><Reference><Citation>Couthouis J., Hart M.P., Erion R., King O.D., Diaz Z., Nakaya T., Ibrahim F., Kim H.-J., Mojsilovic-Petrovic J., Panossian S., et al. Evaluating the role of the FUS/TLS-related gene EWSR1 in amyotrophic lateral sclerosis. Hum. Mol. Genet. 2012;21:2899&#x2013;2911. doi: 10.1093/hmg/dds116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/dds116</ArticleId><ArticleId IdType="pmc">PMC3373238</ArticleId><ArticleId IdType="pubmed">22454397</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneb H.M., Folkmann A.W., Belzil V.V., Jao L.-E., Leblond C.S., Girard S.L., Daoud H., Noreau A., Rochefort D., Hince P., et al. Deleterious mutations in the essential mRNA metabolism factor, hGle1, in amyotrophic lateral sclerosis. Hum. Mol. Genet. 2015;24:1363&#x2013;1373. doi: 10.1093/hmg/ddu545.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu545</ArticleId><ArticleId IdType="pmc">PMC4321443</ArticleId><ArticleId IdType="pubmed">25343993</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng H.-X., Chen W., Hong S.-T., Boycott K.M., Gorrie G.H., Siddique N., Yang Y., Fecto F., Shi Y., Zhai H., et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature. 2011;477:211&#x2013;215. doi: 10.1038/nature10353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10353</ArticleId><ArticleId IdType="pmc">PMC3169705</ArticleId><ArticleId IdType="pubmed">21857683</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobson-Stone C., Luty A.A., Thompson E.M., Blumbergs P., Brooks W.S., Short C.L., Field C.D., Panegyres P.K., Hecker J., Solski J.A., et al. Frontotemporal dementia-amyotrophic lateral sclerosis syndrome locus on chromosome 16p12.1-q12.2: Genetic, clinical and neuropathological analysis. Acta Neuropathol. 2013;125:523&#x2013;533. doi: 10.1007/s00401-013-1078-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1078-9</ArticleId><ArticleId IdType="pmc">PMC3611035</ArticleId><ArticleId IdType="pubmed">23338750</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans C.S., Holzbaur E.L.F. Autophagy and mitophagy in ALS. Neurobiol. Dis. 2019;122:35&#x2013;40. doi: 10.1016/j.nbd.2018.07.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2018.07.005</ArticleId><ArticleId IdType="pmc">PMC6366665</ArticleId><ArticleId IdType="pubmed">29981842</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Z., Sheehan P., Chen S., Yue Z. Is amyotrophic lateral sclerosis/frontotemporal dementia an autophagy disease? Mol. Neurodegener. 2017;12:90. doi: 10.1186/s13024-017-0232-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0232-6</ArticleId><ArticleId IdType="pmc">PMC5746010</ArticleId><ArticleId IdType="pubmed">29282133</ArticleId></ArticleIdList></Reference><Reference><Citation>Budini M., Buratti E., Morselli E., Criollo A. Autophagy and Its Impact on Neurodegenerative Diseases: New Roles for TDP-43 and C9orf72. Front. Mol. Neurosci. 2017;10 doi: 10.3389/fnmol.2017.00170.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00170</ArticleId><ArticleId IdType="pmc">PMC5447761</ArticleId><ArticleId IdType="pubmed">28611593</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesei A., Cortesi M., Zamagni A., Arienti C., Pignatta S., Zanoni M., Paolillo M., Curti D., Rui M., Rossi D., et al. Sigma Receptors as Endoplasmic Reticulum Stress "Gatekeepers" and their Modulators as Emerging New Weapons in the Fight Against Cancer. Front. Pharmacol. 2018;9:711. doi: 10.3389/fphar.2018.00711.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2018.00711</ArticleId><ArticleId IdType="pmc">PMC6048940</ArticleId><ArticleId IdType="pubmed">30042674</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Lim L., Dang M., Song J. A novel mechanism for ATP to enhance the functional oligomerization of TDP-43 by specific binding. Biochem. Biophys. Res. Commun. 2019;514:809&#x2013;814. doi: 10.1016/j.bbrc.2019.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2019.05.006</ArticleId><ArticleId IdType="pubmed">31079926</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard-Marissal N., M&#xe9;dard J.J., Azzedine H., Chrast R. Dysfunction in endoplasmic reticulum-mitochondria crosstalk underlies SIGMAR1 loss of function mediated motor neuron degeneration. Brain. 2015;138:875&#x2013;890. doi: 10.1093/brain/awv008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv008</ArticleId><ArticleId IdType="pubmed">25678561</ArticleId></ArticleIdList></Reference><Reference><Citation>Mavlyutov T.A., Guo L.-W., Epstein M.L., Ruoho A.E. Role of the Sigma-1 receptor in Amyotrophic Lateral Sclerosis (ALS) J. Pharmacol. Sci. 2015;127:10&#x2013;16. doi: 10.1016/j.jphs.2014.12.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jphs.2014.12.013</ArticleId><ArticleId IdType="pmc">PMC4489701</ArticleId><ArticleId IdType="pubmed">25704013</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W., Liu Z., Sun W., Yuan Y., Hu Y., Ni J., Jiao B., Fang L., Li J., Shen L., et al. Mutation analysis of GLT8D1 and ARPP21 genes in amyotrophic lateral sclerosis patients from mainland China. Neurobiol. Aging. 2020;85:156.e151&#x2013;156.e154. doi: 10.1016/j.neurobiolaging.2019.09.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2019.09.013</ArticleId><ArticleId IdType="pubmed">31653410</ArticleId></ArticleIdList></Reference><Reference><Citation>d&#x2019;Azzo A., Tessitore A., Sano R. Gangliosides as apoptotic signals in ER stress response. Cell Death Differ. 2006;13:404&#x2013;414. doi: 10.1038/sj.cdd.4401834.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.cdd.4401834</ArticleId><ArticleId IdType="pubmed">16397581</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu R.K., Tsai Y.-T., Ariga T. Functional Roles of Gangliosides in Neurodevelopment: An Overview of Recent Advances. Neurochem. Res. 2012;37:1230&#x2013;1244. doi: 10.1007/s11064-012-0744-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-012-0744-y</ArticleId><ArticleId IdType="pmc">PMC3895947</ArticleId><ArticleId IdType="pubmed">22410735</ArticleId></ArticleIdList></Reference><Reference><Citation>Moll T., Shaw P.J., Cooper-Knock J. Disrupted glycosylation of lipids and proteins is a cause of neurodegeneration. Brain A J. Neurol. 2020;143:1332&#x2013;1340. doi: 10.1093/brain/awz358.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz358</ArticleId><ArticleId IdType="pmc">PMC7241952</ArticleId><ArticleId IdType="pubmed">31724708</ArticleId></ArticleIdList></Reference><Reference><Citation>Simone M., Trabacca A., Panzeri E., Losito L., Citterio A., Bassi M.T. KIF5A and ALS2 Variants in a Family With Hereditary Spastic Paraplegia and Amyotrophic Lateral Sclerosis. Front. Neurol. 2018;9 doi: 10.3389/fneur.2018.01078.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.01078</ArticleId><ArticleId IdType="pmc">PMC6293196</ArticleId><ArticleId IdType="pubmed">30581417</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura R., Tohnai G., Atsuta N., Nakatochi M., Hayashi N., Watanabe H., Yokoi D., Watanabe H., Katsuno M., Izumi Y., et al. Genetic and functional analysis of KIF5A variants in Japanese patients with sporadic amyotrophic lateral sclerosis. Neurobiol. Aging. 2020 doi: 10.1016/j.neurobiolaging.2020.07.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2020.07.010</ArticleId><ArticleId IdType="pubmed">32888732</ArticleId></ArticleIdList></Reference><Reference><Citation>Chevalier-Larsen E., Holzbaur E.L.F. Axonal transport and neurodegenerative disease. Biochim. Biophys. Acta BBA Mol. Basis Dis. 2006;1762:1094&#x2013;1108. doi: 10.1016/j.bbadis.2006.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2006.04.002</ArticleId><ArticleId IdType="pubmed">16730956</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirokawa N., Niwa S., Tanaka Y. Molecular Motors in Neurons: Transport Mechanisms and Roles in Brain Function, Development, and Disease. Neuron. 2010;68:610&#x2013;638. doi: 10.1016/j.neuron.2010.09.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2010.09.039</ArticleId><ArticleId IdType="pubmed">21092854</ArticleId></ArticleIdList></Reference><Reference><Citation>Millecamps S., Julien J.-P. Axonal transport deficits and neurodegenerative diseases. Nat. Rev. Neurosci. 2013;14:161&#x2013;176. doi: 10.1038/nrn3380.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3380</ArticleId><ArticleId IdType="pubmed">23361386</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanai Y., Dohmae N., Hirokawa N. Kinesin Transports RNA: Isolation and Characterization of an RNA-Transporting Granule. Neuron. 2004;43:513&#x2013;525. doi: 10.1016/j.neuron.2004.07.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2004.07.022</ArticleId><ArticleId IdType="pubmed">15312650</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O&#x2019;Regan J.P., Deng H.X., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59&#x2013;62. doi: 10.1038/362059a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J.H., Elpers C., Reunert J., McCormick M.L., Mohr J., Biskup S., Schwartz O., Rust S., Gr&#xfc;neberg M., Seelh&#xf6;fer A., et al. SOD1 deficiency: A novel syndrome distinct from amyotrophic lateral sclerosis. Brain. 2019;142:2230&#x2013;2237. doi: 10.1093/brain/awz182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz182</ArticleId><ArticleId IdType="pmc">PMC6658856</ArticleId><ArticleId IdType="pubmed">31332433</ArticleId></ArticleIdList></Reference><Reference><Citation>Huai J., Zhang Z. Structural Properties and Interaction Partners of Familial ALS-Associated SOD1 Mutants. Front. Neurol. 2019;10 doi: 10.3389/fneur.2019.00527.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00527</ArticleId><ArticleId IdType="pmc">PMC6536575</ArticleId><ArticleId IdType="pubmed">31164862</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita S., Ando Y. Genotype-phenotype relationship in hereditary amyotrophic lateral sclerosis. Transl. Neurodegener. 2015;4:13. doi: 10.1186/s40035-015-0036-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-015-0036-y</ArticleId><ArticleId IdType="pmc">PMC4513711</ArticleId><ArticleId IdType="pubmed">26213621</ArticleId></ArticleIdList></Reference><Reference><Citation>Abel O., Powell J.F., Andersen P.M., Al-Chalabi A. ALSoD: A user-friendly online bioinformatics tool for amyotrophic lateral sclerosis genetics. Hum. Mutat. 2012;33:1345&#x2013;1351. doi: 10.1002/humu.22157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.22157</ArticleId><ArticleId IdType="pubmed">22753137</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasinelli P., Brown R.H. Molecular biology of amyotrophic lateral sclerosis: Insights from genetics. Nat. Rev. Neurosci. 2006;7:710&#x2013;723. doi: 10.1038/nrn1971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn1971</ArticleId><ArticleId IdType="pubmed">16924260</ArticleId></ArticleIdList></Reference><Reference><Citation>Azadmanesh J., Borgstahl G.E.O. A Review of the Catalytic Mechanism of Human Manganese Superoxide Dismutase. Antioxidants. 2018;7:25. doi: 10.3390/antiox7020025.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox7020025</ArticleId><ArticleId IdType="pmc">PMC5836015</ArticleId><ArticleId IdType="pubmed">29385710</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur S.J., McKeown S.R., Rashid S. Mutant SOD1 mediated pathogenesis of Amyotrophic Lateral Sclerosis. Gene. 2016;577:109&#x2013;118. doi: 10.1016/j.gene.2015.11.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gene.2015.11.049</ArticleId><ArticleId IdType="pubmed">26657039</ArticleId></ArticleIdList></Reference><Reference><Citation>Julien J.P. Amyotrophic lateral sclerosis. Unfolding the toxicity of the misfolded. Cell. 2001;104:581&#x2013;591. doi: 10.1016/S0092-8674(01)00244-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(01)00244-6</ArticleId><ArticleId IdType="pubmed">11239414</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi Y., Homma K., Ichijo H. SOD1 in neurotoxicity and its controversial roles in SOD1 mutation-negative ALS. Adv. Biol. Regul. 2016;60:95&#x2013;104. doi: 10.1016/j.jbior.2015.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbior.2015.10.006</ArticleId><ArticleId IdType="pubmed">26563614</ArticleId></ArticleIdList></Reference><Reference><Citation>Boill&#xe9;e S., Vande Velde C., Cleveland D.W. ALS: A Disease of Motor Neurons and Their Nonneuronal Neighbors. Neuron. 2006;52:39&#x2013;59. doi: 10.1016/j.neuron.2006.09.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2006.09.018</ArticleId><ArticleId IdType="pubmed">17015226</ArticleId></ArticleIdList></Reference><Reference><Citation>Par&#xe9; B., Lehmann M., Beaudin M., Nordstr&#xf6;m U., Saikali S., Julien J.-P., Gilthorpe J.D., Marklund S.L., Cashman N.R., Andersen P.M., et al. Misfolded SOD1 pathology in sporadic Amyotrophic Lateral Sclerosis. Sci. Rep. 2018;8:14223. doi: 10.1038/s41598-018-31773-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-31773-z</ArticleId><ArticleId IdType="pmc">PMC6155098</ArticleId><ArticleId IdType="pubmed">30242181</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunton-Stasyshyn R.K., Saccon R.A., Fratta P., Fisher E.M. SOD1 Function and Its Implications for Amyotrophic Lateral Sclerosis Pathology: New and Renascent Themes. Neuroscientist. 2015;21:519&#x2013;529. doi: 10.1177/1073858414561795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1073858414561795</ArticleId><ArticleId IdType="pubmed">25492944</ArticleId></ArticleIdList></Reference><Reference><Citation>Tafuri F., Ronchi D., Magri F., Comi G.P., Corti S. SOD1 misplacing and mitochondrial dysfunction in amyotrophic lateral sclerosis pathogenesis. Front. Cell. Neurosci. 2015;9:336. doi: 10.3389/fncel.2015.00336.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2015.00336</ArticleId><ArticleId IdType="pmc">PMC4548205</ArticleId><ArticleId IdType="pubmed">26379505</ArticleId></ArticleIdList></Reference><Reference><Citation>Pansarasa O., Bordoni M., Diamanti L., Sproviero D., Gagliardi S., Cereda C. SOD1 in Amyotrophic Lateral Sclerosis: "Ambivalent" Behavior Connected to the Disease. Int. J. Mol. Sci. 2018;19:1345. doi: 10.3390/ijms19051345.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19051345</ArticleId><ArticleId IdType="pmc">PMC5983710</ArticleId><ArticleId IdType="pubmed">29751510</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis S., Couratier P., Julian A., Vallat J.M., Corcia P., Le Masson G. Management and therapeutic perspectives in amyotrophic lateral sclerosis. Expert Rev. Neurother. 2017;17:263&#x2013;276. doi: 10.1080/14737175.2016.1227705.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737175.2016.1227705</ArticleId><ArticleId IdType="pubmed">27644548</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain K.K. Neuroprotection in Amyotrophic Lateral Sclerosis. In: Jain K.K., editor. The Handbook of Neuroprotection. Springer; New York, NY, USA: 2019.</Citation></Reference><Reference><Citation>Andersen P.M., Nilsson P., Keranen M.L., Forsgren L., Hagglund J., Karlsborg M., Ronnevi L.O., Gredal O., Marklund S.L. Phenotypic heterogeneity in motor neuron disease patients with CuZn-superoxide dismutase mutations in Scandinavia. Brain. 1997;120:1723&#x2013;1737. doi: 10.1093/brain/120.10.1723.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/120.10.1723</ArticleId><ArticleId IdType="pubmed">9365366</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P., Valdmanis P., Millecamps S., Lionnet C., Blasco H., Mouzat K., Daoud H., Belzil V., Morales R., Pageot N., et al. Phenotype and genotype analysis in amyotrophic lateral sclerosis with TARDBP gene mutations. Neurology. 2012;78:1519&#x2013;1526. doi: 10.1212/WNL.0b013e3182553c88.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182553c88</ArticleId><ArticleId IdType="pubmed">22539580</ArticleId></ArticleIdList></Reference><Reference><Citation>Leigh P.N., Whitwell H., Garofalo O., Buller J., Swash M., Martin J.E., Gallo J.M., Weller R.O., Anderton B.H. Ubiquitin-immunoreactive intraneuronal inclusions in amyotrophic lateral sclerosis. Morphology, distribution, and specificity. Brain. 1991;114:775&#x2013;788. doi: 10.1093/brain/114.2.775.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/114.2.775</ArticleId><ArticleId IdType="pubmed">1646064</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T., Hasegawa M., Akiyama H., Ikeda K., Nonaka T., Mori H., Mann D., Tsuchiya K., Yoshida M., Hashizume Y., et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 2006;351:602&#x2013;611. doi: 10.1016/j.bbrc.2006.10.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.10.093</ArticleId><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitcho M.A., Baloh R.H., Chakraverty S., Mayo K., Norton J.B., Levitch D., Hatanpaa K.J., White C.L., 3rd, Bigio E.H., Caselli R., et al. TDP-43 A315T mutation in familial motor neuron disease. Ann. Neurol. 2008;63:535&#x2013;538. doi: 10.1002/ana.21344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21344</ArticleId><ArticleId IdType="pmc">PMC2747362</ArticleId><ArticleId IdType="pubmed">18288693</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E., Valdmanis P.N., Dion P., Spiegelman D., McConkey B.J., Vande Velde C., Bouchard J.P., Lacomblez L., Pochigaeva K., Salachas F., et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat. Genet. 2008;40:572&#x2013;574. doi: 10.1038/ng.132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.132</ArticleId><ArticleId IdType="pubmed">18372902</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Deerlin V.M., Leverenz J.B., Bekris L.M., Bird T.D., Yuan W., Elman L.B., Clay D., Wood E.M., Chen-Plotkin A.S., Martinez-Lage M., et al. TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: A genetic and histopathological analysis. Lancet Neurol. 2008;7:409&#x2013;416. doi: 10.1016/S1474-4422(08)70071-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(08)70071-1</ArticleId><ArticleId IdType="pmc">PMC3546119</ArticleId><ArticleId IdType="pubmed">18396105</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoseki A., Shiga A., Tan C.F., Tagawa A., Kaneko H., Koyama A., Eguchi H., Tsujino A., Ikeuchi T., Kakita A., et al. TDP-43 mutation in familial amyotrophic lateral sclerosis. Ann. Neurol. 2008;63:538&#x2013;542. doi: 10.1002/ana.21392.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21392</ArticleId><ArticleId IdType="pubmed">18438952</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattante S., Rouleau G.A., Kabashi E. TARDBP and FUS mutations associated with amyotrophic lateral sclerosis: Summary and update. Hum. Mutat. 2013;34:812&#x2013;826. doi: 10.1002/humu.22319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.22319</ArticleId><ArticleId IdType="pubmed">23559573</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E., Brindisi A., Giombi M., Tisminetzky S., Ayala Y.M., Baralle F.E. TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail: An important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing. J. Biol. Chem. 2005;280:37572&#x2013;37584. doi: 10.1074/jbc.M505557200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M505557200</ArticleId><ArticleId IdType="pubmed">16157593</ArticleId></ArticleIdList></Reference><Reference><Citation>Giordana M.T., Piccinini M., Grifoni S., De Marco G., Vercellino M., Magistrello M., Pellerino A., Buccinna B., Lupino E., Rinaudo M.T. TDP-43 redistribution is an early event in sporadic amyotrophic lateral sclerosis. Brain Pathol. 2010;20:351&#x2013;360. doi: 10.1111/j.1750-3639.2009.00284.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1750-3639.2009.00284.x</ArticleId><ArticleId IdType="pubmed">19338576</ArticleId></ArticleIdList></Reference><Reference><Citation>Schipper L.J., Raaphorst J., Aronica E., Baas F., de Haan R., de Visser M., Troost D. Prevalence of brain and spinal cord inclusions, including dipeptide repeat proteins, in patients with the C9ORF72 hexanucleotide repeat expansion: A systematic neuropathological review. Neuropathol. Appl. Neurobiol. 2016;42:547&#x2013;560. doi: 10.1111/nan.12284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12284</ArticleId><ArticleId IdType="pubmed">26373655</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi R., Tada M., Shiga A., Toyoshima Y., Konno T., Sato T., Nozaki H., Kato T., Horie M., Shimizu H., et al. Heterogeneity of cerebral TDP-43 pathology in sporadic amyotrophic lateral sclerosis: Evidence for clinico-pathologic subtypes. Acta Neuropathol. Commun. 2016;4:61. doi: 10.1186/s40478-016-0335-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0335-2</ArticleId><ArticleId IdType="pmc">PMC4918136</ArticleId><ArticleId IdType="pubmed">27338935</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E., Baralle F.E. The multiple roles of TDP-43 in pre-mRNA processing and gene expression regulation. RNA Biol. 2010;7:420&#x2013;429. doi: 10.4161/rna.7.4.12205.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/rna.7.4.12205</ArticleId><ArticleId IdType="pubmed">20639693</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala Y.M., Zago P., D&#x2019;Ambrogio A., Xu Y.F., Petrucelli L., Buratti E., Baralle F.E. Structural determinants of the cellular localization and shuttling of TDP-43. J. Cell Sci. 2008;121:3778&#x2013;3785. doi: 10.1242/jcs.038950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.038950</ArticleId><ArticleId IdType="pubmed">18957508</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratti A., Buratti E. Physiological functions and pathobiology of TDP-43 and FUS/TLS proteins. J. Neurochem. 2016;138:95&#x2013;111. doi: 10.1111/jnc.13625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13625</ArticleId><ArticleId IdType="pubmed">27015757</ArticleId></ArticleIdList></Reference><Reference><Citation>Winton M.J., Igaz L.M., Wong M.M., Kwong L.K., Trojanowski J.Q., Lee V.M.Y. Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. J. Biol. Chem. 2008;283:13302&#x2013;13309. doi: 10.1074/jbc.M800342200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M800342200</ArticleId><ArticleId IdType="pmc">PMC2442318</ArticleId><ArticleId IdType="pubmed">18305110</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E., Baralle F.E. Multiple roles of TDP-43 in gene expression, splicing regulation, and human disease. Front. Biosci. 2008;13:867&#x2013;878. doi: 10.2741/2727.</Citation><ArticleIdList><ArticleId IdType="doi">10.2741/2727</ArticleId><ArticleId IdType="pubmed">17981595</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong M.J., Volkening K., Hammond R., Yang W., Strong W., Leystra-Lantz C., Shoesmith C. TDP43 is a human low molecular weight neurofilament (hNFL) mRNA-binding protein. Mol. Cell Neurosci. 2007;35:320&#x2013;327. doi: 10.1016/j.mcn.2007.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2007.03.007</ArticleId><ArticleId IdType="pubmed">17481916</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao M., Kim J.R., van Bruggen R., Park J. RNA-Binding Proteins in Amyotrophic Lateral Sclerosis. Mol. Cells. 2018;41:818&#x2013;829. doi: 10.14348/molcells.2018.0243.</Citation><ArticleIdList><ArticleId IdType="doi">10.14348/molcells.2018.0243</ArticleId><ArticleId IdType="pmc">PMC6182225</ArticleId><ArticleId IdType="pubmed">30157547</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala Y.M., Misteli T., Baralle F.E. TDP-43 regulates retinoblastoma protein phosphorylation through the repression of cyclin-dependent kinase 6 expression. Proc. Natl. Acad. Sci. USA. 2008;105:3785&#x2013;3789. doi: 10.1073/pnas.0800546105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0800546105</ArticleId><ArticleId IdType="pmc">PMC2268791</ArticleId><ArticleId IdType="pubmed">18305152</ArticleId></ArticleIdList></Reference><Reference><Citation>Woerner A.C., Frottin F., Hornburg D., Feng L.R., Meissner F., Patra M., Tatzelt J., Mann M., Winklhofer K.F., Hartl F.U., et al. Cytoplasmic protein aggregates interfere with nucleocytoplasmic transport of protein and RNA. Science. 2016;351:173&#x2013;176. doi: 10.1126/science.aad2033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aad2033</ArticleId><ArticleId IdType="pubmed">26634439</ArticleId></ArticleIdList></Reference><Reference><Citation>Butti Z., Patten S.A. RNA Dysregulation in Amyotrophic Lateral Sclerosis. Front. Genet. 2019;9:712. doi: 10.3389/fgene.2018.00712.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2018.00712</ArticleId><ArticleId IdType="pmc">PMC6349704</ArticleId><ArticleId IdType="pubmed">30723494</ArticleId></ArticleIdList></Reference><Reference><Citation>Hergesheimer R.C., Chami A.A., de Assis D.R., Vourc&#x2019;h P., Andres C.R., Corcia P., Lanznaster D., Blasco H. The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis: A resolution in sight? Brain A J. Neurol. 2019;142:1176&#x2013;1194. doi: 10.1093/brain/awz078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz078</ArticleId><ArticleId IdType="pmc">PMC6487324</ArticleId><ArticleId IdType="pubmed">30938443</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad A., Bharathi V., Sivalingam V., Girdhar A., Patel B.K. Molecular Mechanisms of TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis. Front. Mol. Neurosci. 2019;12 doi: 10.3389/fnmol.2019.00025.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2019.00025</ArticleId><ArticleId IdType="pmc">PMC6382748</ArticleId><ArticleId IdType="pubmed">30837838</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed Z.E., L&#xf3;pez-Erauskin J., Baughn M.W., Zhang O., Drenner K., Sun Y., Freyermuth F., McMahon M.A., Beccari M.S., Artates J.W., et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat. Neurosci. 2019;22:180&#x2013;190. doi: 10.1038/s41593-018-0293-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0293-z</ArticleId><ArticleId IdType="pmc">PMC6348009</ArticleId><ArticleId IdType="pubmed">30643298</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M., Humphrey J., Pickles S., Brown A.-L., Hill S.E., Kachergus J.M., Shi J., Heckman M.G., Spiegel M.R., Cook C., et al. Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. J. Clin. Investig. 2020;130:6080&#x2013;6092. doi: 10.1172/JCI139741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI139741</ArticleId><ArticleId IdType="pmc">PMC7598060</ArticleId><ArticleId IdType="pubmed">32790644</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C., Polymenidou M., Hutt K.R., Vu A.Q., Baughn M., Huelga S.C., Clutario K.M., Ling S.C., Liang T.Y., Mazur C., et al. Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. Nat. Neurosci. 2012;15:1488&#x2013;1497. doi: 10.1038/nn.3230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3230</ArticleId><ArticleId IdType="pmc">PMC3586380</ArticleId><ArticleId IdType="pubmed">23023293</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyce P.I., Fratta P., Fisher E.M., Acevedo-Arozena A. SOD1 and TDP-43 animal models of amyotrophic lateral sclerosis: Recent advances in understanding disease toward the development of clinical treatments. Mamm. Genome. 2011;22:420&#x2013;448. doi: 10.1007/s00335-011-9339-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00335-011-9339-1</ArticleId><ArticleId IdType="pubmed">21706386</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsao W., Jeong Y.H., Lin S., Ling J., Price D.L., Chiang P.M., Wong P.C. Rodent models of TDP-43: Recent advances. Brain Res. 2012;1462:26&#x2013;39. doi: 10.1016/j.brainres.2012.04.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2012.04.031</ArticleId><ArticleId IdType="pmc">PMC3613131</ArticleId><ArticleId IdType="pubmed">22608070</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z.S. Does a loss of TDP-43 function cause neurodegeneration? Mol. Neurodegener. 2012;7:27. doi: 10.1186/1750-1326-7-27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-7-27</ArticleId><ArticleId IdType="pmc">PMC3419078</ArticleId><ArticleId IdType="pubmed">22697423</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebstein S.Y., Yagudayeva I., Shneider N.A. Mutant TDP-43 Causes Early-Stage Dose-Dependent Motor Neuron Degeneration in a TARDBP Knockin Mouse Model of ALS. Cell Rep. 2019;26:364&#x2013;373.e364. doi: 10.1016/j.celrep.2018.12.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2018.12.045</ArticleId><ArticleId IdType="pubmed">30625319</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe S., Oiwa K., Murata Y., Komine O., Sobue A., Endo F., Takahashi E., Yamanaka K. ALS-linked TDP-43M337V knock-in mice exhibit splicing deregulation without neurodegeneration. Mol. Brain. 2020;13:8. doi: 10.1186/s13041-020-0550-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-020-0550-4</ArticleId><ArticleId IdType="pmc">PMC6971932</ArticleId><ArticleId IdType="pubmed">31959210</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C., Rogelj B., Hortobagyi T., De Vos K.J., Nishimura A.L., Sreedharan J., Hu X., Smith B., Ruddy D., Wright P., et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323:1208&#x2013;1211. doi: 10.1126/science.1165942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1165942</ArticleId><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>Millecamps S., Salachas F., Cazeneuve C., Gordon P., Bricka B., Camuzat A., Guillot-Noel L., Russaouen O., Bruneteau G., Pradat P.F., et al. SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis: Genotype-phenotype correlations. J. Med. Genet. 2010;47:554&#x2013;560. doi: 10.1136/jmg.2010.077180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmg.2010.077180</ArticleId><ArticleId IdType="pubmed">20577002</ArticleId></ArticleIdList></Reference><Reference><Citation>Waibel S., Neumann M., Rosenbohm A., Birve A., Volk A.E., Weishaupt J.H., Meyer T., Muller U., Andersen P.M., Ludolph A.C. Truncating mutations in FUS/TLS give rise to a more aggressive ALS-phenotype than missense mutations: A clinico-genetic study in Germany. Eur. J. Neurol. 2013;20:540&#x2013;546. doi: 10.1111/ene.12031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12031</ArticleId><ArticleId IdType="pubmed">23217123</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A., Calvo A., Mazzini L., Cantello R., Mora G., Moglia C., Corrado L., D&#x2019;Alfonso S., Majounie E., Renton A., et al. Extensive genetics of ALS: A population-based study in Italy. Neurology. 2012;79:1983&#x2013;1989. doi: 10.1212/WNL.0b013e3182735d36.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182735d36</ArticleId><ArticleId IdType="pmc">PMC3484987</ArticleId><ArticleId IdType="pubmed">23100398</ArticleId></ArticleIdList></Reference><Reference><Citation>Hubers A., Just W., Rosenbohm A., Muller K., Marroquin N., Goebel I., Hogel J., Thiele H., Altmuller J., Nurnberg P., et al. De novo FUS mutations are the most frequent genetic cause in early-onset German ALS patients. Neurobiol. Aging. 2015;36:3117.e3111&#x2013;3117.e3116. doi: 10.1016/j.neurobiolaging.2015.08.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.08.005</ArticleId><ArticleId IdType="pubmed">26362943</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinszner H., Sok J., Immanuel D., Yin Y., Ron D. TLS (FUS) binds RNA in vivo and engages in nucleo-cytoplasmic shuttling. J. Cell Sci. 1997;110:1741&#x2013;1750.</Citation><ArticleIdList><ArticleId IdType="pubmed">9264461</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H.J., Taylor J.P. Lost in Transportation: Nucleocytoplasmic Transport Defects in ALS and Other Neurodegenerative Diseases. Neuron. 2017;96:285&#x2013;297. doi: 10.1016/j.neuron.2017.07.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.07.029</ArticleId><ArticleId IdType="pmc">PMC5678982</ArticleId><ArticleId IdType="pubmed">29024655</ArticleId></ArticleIdList></Reference><Reference><Citation>Belly A., Moreau-Gachelin F., Sadoul R., Goldberg Y. Delocalization of the multifunctional RNA splicing factor TLS/FUS in hippocampal neurones: Exclusion from the nucleus and accumulation in dendritic granules and spine heads. Neurosci. Lett. 2005;379:152&#x2013;157. doi: 10.1016/j.neulet.2004.12.071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2004.12.071</ArticleId><ArticleId IdType="pubmed">15843054</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda K., Zhang H., Loiselle D., Haystead T., Macara I.G., Mili S. The RNA-binding protein Fus directs translation of localized mRNAs in APC-RNP granules. J. Cell. Biol. 2013;203:737&#x2013;746. doi: 10.1083/jcb.201306058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201306058</ArticleId><ArticleId IdType="pmc">PMC3857475</ArticleId><ArticleId IdType="pubmed">24297750</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu-Yesucevitz L., Bassell G.J., Gitler A.D., Hart A.C., Klann E., Richter J.D., Warren S.T., Wolozin B. Local RNA translation at the synapse and in disease. J. Neurosci. 2011;31:16086&#x2013;16093. doi: 10.1523/JNEUROSCI.4105-11.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4105-11.2011</ArticleId><ArticleId IdType="pmc">PMC3241995</ArticleId><ArticleId IdType="pubmed">22072660</ArticleId></ArticleIdList></Reference><Reference><Citation>Sephton C.F., Tang A.A., Kulkarni A., West J., Brooks M., Stubblefield J.J., Liu Y., Zhang M.Q., Green C.B., Huber K.M., et al. Activity-dependent FUS dysregulation disrupts synaptic homeostasis. Proc. Natl. Acad. Sci. USA. 2014;111:E4769&#x2013;E4778. doi: 10.1073/pnas.1406162111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1406162111</ArticleId><ArticleId IdType="pmc">PMC4226112</ArticleId><ArticleId IdType="pubmed">25324524</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamelgarn M., Chen J., Kuang L., Jin H., Kasarskis E.J., Zhu H. ALS mutations of FUS suppress protein translation and disrupt the regulation of nonsense-mediated decay. Proc. Natl. Acad. Sci. USA. 2018;115:E11904. doi: 10.1073/pnas.1810413115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1810413115</ArticleId><ArticleId IdType="pmc">PMC6304956</ArticleId><ArticleId IdType="pubmed">30455313</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakaya T., Maragkakis M. Amyotrophic Lateral Sclerosis associated FUS mutation shortens mitochondria and induces neurotoxicity. Sci. Rep. 2018;8:15575. doi: 10.1038/s41598-018-33964-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-33964-0</ArticleId><ArticleId IdType="pmc">PMC6197261</ArticleId><ArticleId IdType="pubmed">30349096</ArticleId></ArticleIdList></Reference><Reference><Citation>Kino Y., Washizu C., Kurosawa M., Yamada M., Miyazaki H., Akagi T., Hashikawa T., Doi H., Takumi T., Hicks G.G., et al. FUS/TLS deficiency causes behavioral and pathological abnormalities distinct from amyotrophic lateral sclerosis. Acta Neuropathol. Commun. 2015;3:24. doi: 10.1186/s40478-015-0202-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-015-0202-6</ArticleId><ArticleId IdType="pmc">PMC4408580</ArticleId><ArticleId IdType="pubmed">25907258</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma A., Lyashchenko A.K., Lu L., Nasrabady S.E., Elmaleh M., Mendelsohn M., Nemes A., Tapia J.C., Mentis G.Z., Shneider N.A. ALS-associated mutant FUS induces selective motor neuron degeneration through toxic gain of function. Nat. Commun. 2016;7:10465. doi: 10.1038/ncomms10465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms10465</ArticleId><ArticleId IdType="pmc">PMC4742863</ArticleId><ArticleId IdType="pubmed">26842965</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasayama H., Shimamura M., Tokuda T., Azuma Y., Yoshida T., Mizuno T., Nakagawa M., Fujikake N., Nagai Y., Yamaguchi M. Knockdown of the Drosophila fused in sarcoma (FUS) homologue causes deficient locomotive behavior and shortening of motoneuron terminal branches. PLoS ONE. 2012;7:e39483. doi: 10.1371/journal.pone.0039483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0039483</ArticleId><ArticleId IdType="pmc">PMC3378546</ArticleId><ArticleId IdType="pubmed">22724023</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Zhou H., Tong J., Chen H., Liu Y.J., Wang D., Wei X., Xia X.G. FUS transgenic rats develop the phenotypes of amyotrophic lateral sclerosis and frontotemporal lobar degeneration. PLoS Genet. 2011;7:e1002011. doi: 10.1371/journal.pgen.1002011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1002011</ArticleId><ArticleId IdType="pmc">PMC3048370</ArticleId><ArticleId IdType="pubmed">21408206</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Yang M., Deng J., Chen X., Ye Y., Zhu L., Liu J., Ye H., Shen Y., Li Y., et al. Expression of human FUS protein in Drosophila leads to progressive neurodegeneration. Protein Cell. 2011;2:477&#x2013;486. doi: 10.1007/s13238-011-1065-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13238-011-1065-7</ArticleId><ArticleId IdType="pmc">PMC3563268</ArticleId><ArticleId IdType="pubmed">21748598</ArticleId></ArticleIdList></Reference><Reference><Citation>An H., Skelt L., Notaro A., Highley J.R., Fox A.H., La Bella V., Buchman V.L., Shelkovnikova T.A. ALS-linked FUS mutations confer loss and gain of function in the nucleus by promoting excessive formation of dysfunctional paraspeckles. Acta Neuropathol. Commun. 2019;7:7. doi: 10.1186/s40478-019-0658-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0658-x</ArticleId><ArticleId IdType="pmc">PMC6330737</ArticleId><ArticleId IdType="pubmed">30642400</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton A.E., Majounie E., Waite A., Simon-Sanchez J., Rollinson S., Gibbs J.R., Schymick J.C., Laaksovirta H., van Swieten J.C., Myllykangas L., et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;268. doi: 10.1016/j.neuron.2011.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacoangeli A., Al Khleifat A., Jones A.R., Sproviero W., Shatunov A., Opie-Martin S., Morrison K.E., Shaw P.J., Shaw C.E., Fogh I., et al. C9orf72 intermediate expansions of 24&#x2013;30 repeats are associated with ALS. Acta Neuropathol. Commun. 2019;7:115. doi: 10.1186/s40478-019-0724-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0724-4</ArticleId><ArticleId IdType="pmc">PMC6637621</ArticleId><ArticleId IdType="pubmed">31315673</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R., Isaacs A.M. C9orf72-mediated ALS and FTD: Multiple pathways to disease. Nat. Rev. Neurol. 2018;14:544&#x2013;558. doi: 10.1038/s41582-018-0047-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0047-2</ArticleId><ArticleId IdType="pmc">PMC6417666</ArticleId><ArticleId IdType="pubmed">30120348</ArticleId></ArticleIdList></Reference><Reference><Citation>Haeusler A.R., Donnelly C.J., Rothstein J.D. The expanding biology of the C9orf72 nucleotide repeat expansion in neurodegenerative disease. Nat. Rev. Neurosci. 2016;17:383&#x2013;395. doi: 10.1038/nrn.2016.38.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn.2016.38</ArticleId><ArticleId IdType="pmc">PMC7376590</ArticleId><ArticleId IdType="pubmed">27150398</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoki Y., Manzano R., Lee Y., Dafinca R., Aoki M., Douglas A.G.L., Varela M.A., Sathyaprakash C., Scaber J., Barbagallo P., et al. C9orf72 and RAB7L1 regulate vesicle trafficking in amyotrophic lateral sclerosis and frontotemporal dementia. Brain. 2017;140:887&#x2013;897. doi: 10.1093/brain/awx024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx024</ArticleId><ArticleId IdType="pubmed">28334866</ArticleId></ArticleIdList></Reference><Reference><Citation>Nassif M., Woehlbier U., Manque P.A. The Enigmatic Role of C9ORF72 in Autophagy. Front. Neurosci. 2017;11:442. doi: 10.3389/fnins.2017.00442.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2017.00442</ArticleId><ArticleId IdType="pmc">PMC5541066</ArticleId><ArticleId IdType="pubmed">28824365</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S., Isaacs A.M. C9orf72 amyotrophic lateral sclerosis and frontotemporal dementia: Gain or loss of function? Curr. Opin. Neurol. 2014;27:515&#x2013;523. doi: 10.1097/WCO.0000000000000130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000130</ArticleId><ArticleId IdType="pmc">PMC4165481</ArticleId><ArticleId IdType="pubmed">25188012</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K., Donnelly C.J., Haeusler A.R., Grima J.C., Machamer J.B., Steinwald P., Daley E.L., Miller S.J., Cunningham K.M., Vidensky S., et al. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature. 2015;525:56&#x2013;61. doi: 10.1038/nature14973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14973</ArticleId><ArticleId IdType="pmc">PMC4800742</ArticleId><ArticleId IdType="pubmed">26308891</ArticleId></ArticleIdList></Reference><Reference><Citation>Farg M.A., Sundaramoorthy V., Sultana J.M., Yang S., Atkinson R.A., Levina V., Halloran M.A., Gleeson P.A., Blair I.P., Soo K.Y., et al. C9ORF72, implicated in amytrophic lateral sclerosis and frontotemporal dementia, regulates endosomal trafficking. Hum. Mol. Genet. 2014;23:3579&#x2013;3595. doi: 10.1093/hmg/ddu068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu068</ArticleId><ArticleId IdType="pmc">PMC4049310</ArticleId><ArticleId IdType="pubmed">24549040</ArticleId></ArticleIdList></Reference><Reference><Citation>Burk K., Pasterkamp R.J. Disrupted neuronal trafficking in amyotrophic lateral sclerosis. Acta Neuropathol. 2019;137:859&#x2013;877. doi: 10.1007/s00401-019-01964-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-01964-7</ArticleId><ArticleId IdType="pmc">PMC6531423</ArticleId><ArticleId IdType="pubmed">30721407</ArticleId></ArticleIdList></Reference><Reference><Citation>Hubers A., Marroquin N., Schmoll B., Vielhaber S., Just M., Mayer B., Hogel J., Dorst J., Mertens T., Just W., et al. Polymerase chain reaction and Southern blot-based analysis of the C9orf72 hexanucleotide repeat in different motor neuron diseases. Neurobiol. Aging. 2014;35:1214.e1&#x2013;1214.e6. doi: 10.1016/j.neurobiolaging.2013.11.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.11.034</ArticleId><ArticleId IdType="pubmed">24378086</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeve B.F., Boylan K.B., Graff-Radford N.R., DeJesus-Hernandez M., Knopman D.S., Pedraza O., Vemuri P., Jones D., Lowe V., Murray M.E., et al. Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain. 2012;135:765&#x2013;783. doi: 10.1093/brain/aws004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aws004</ArticleId><ArticleId IdType="pmc">PMC3286335</ArticleId><ArticleId IdType="pubmed">22366793</ArticleId></ArticleIdList></Reference><Reference><Citation>Devenney E., Hornberger M., Irish M., Mioshi E., Burrell J., Tan R., Kiernan M.C., Hodges J.R. Frontotemporal dementia associated with the C9ORF72 mutation: A unique clinical profile. JAMA Neurol. 2014;71:331&#x2013;339. doi: 10.1001/jamaneurol.2013.6002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.6002</ArticleId><ArticleId IdType="pubmed">24445580</ArticleId></ArticleIdList></Reference><Reference><Citation>Waite A.J., Baumer D., East S., Neal J., Morris H.R., Ansorge O., Blake D.J. Reduced C9orf72 protein levels in frontal cortex of amyotrophic lateral sclerosis and frontotemporal degeneration brain with the C9ORF72 hexanucleotide repeat expansion. Neurobiol. Aging. 2014;35:1779.e5&#x2013;1779.e13. doi: 10.1016/j.neurobiolaging.2014.01.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.01.016</ArticleId><ArticleId IdType="pmc">PMC3988882</ArticleId><ArticleId IdType="pubmed">24559645</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao S., MacNair L., McGoldrick P., McKeever P.M., McLean J.R., Zhang M., Keith J., Zinman L., Rogaeva E., Robertson J. Isoform-specific antibodies reveal distinct subcellular localizations of C9orf72 in amyotrophic lateral sclerosis. Ann. Neurol. 2015;78:568&#x2013;583. doi: 10.1002/ana.24469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24469</ArticleId><ArticleId IdType="pubmed">26174152</ArticleId></ArticleIdList></Reference><Reference><Citation>Koppers M., Blokhuis A.M., Westeneng H.J., Terpstra M.L., Zundel C.A., Vieira de Sa R., Schellevis R.D., Waite A.J., Blake D.J., Veldink J.H., et al. C9orf72 ablation in mice does not cause motor neuron degeneration or motor deficits. Ann. Neurol. 2015;78:426&#x2013;438. doi: 10.1002/ana.24453.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24453</ArticleId><ArticleId IdType="pmc">PMC4744979</ArticleId><ArticleId IdType="pubmed">26044557</ArticleId></ArticleIdList></Reference><Reference><Citation>Foxe D., Elan E., Burrell J.R., Leslie F.V.C., Devenney E., Kwok J.B., Halliday G.M., Hodges J.R., Piguet O. Intrafamilial Phenotypic Variability in the C9orf72 Gene Expansion: 2 Case Studies. Front. Psychol. 2018;9:1615. doi: 10.3389/fpsyg.2018.01615.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyg.2018.01615</ArticleId><ArticleId IdType="pmc">PMC6129762</ArticleId><ArticleId IdType="pubmed">30233460</ArticleId></ArticleIdList></Reference><Reference><Citation>Couthouis J., Hart M.P., Shorter J., DeJesus-Hernandez M., Erion R., Oristano R., Liu A.X., Ramos D., Jethava N., Hosangadi D., et al. A yeast functional screen predicts new candidate ALS disease genes. Proc. Natl. Acad. Sci. USA. 2011;108:20881. doi: 10.1073/pnas.1109434108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1109434108</ArticleId><ArticleId IdType="pmc">PMC3248518</ArticleId><ArticleId IdType="pubmed">22065782</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon Y., Park H., Kim S., Nguyen P.T., Hyeon S.J., Chung S., Im H., Lee J., Lee S.B., Ryu H. Genetic Ablation of EWS RNA Binding Protein 1 (EWSR1) Leads to Neuroanatomical Changes and Motor Dysfunction in Mice. Exp. Neurobiol. 2018;27:103&#x2013;111. doi: 10.5607/en.2018.27.2.103.</Citation><ArticleIdList><ArticleId IdType="doi">10.5607/en.2018.27.2.103</ArticleId><ArticleId IdType="pmc">PMC5934541</ArticleId><ArticleId IdType="pubmed">29731676</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattante S., Pomponi M.G., Conte A., Marangi G., Bisogni G., Patanella A.K., Meleo E., Lunetta C., Riva N., Mosca L., et al. ATXN1 intermediate-length polyglutamine expansions are associated with amyotrophic lateral sclerosis. Neurobiol. Aging. 2018;64:157.e151&#x2013;157.e155. doi: 10.1016/j.neurobiolaging.2017.11.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.11.011</ArticleId><ArticleId IdType="pubmed">29274668</ArticleId></ArticleIdList></Reference><Reference><Citation>Aditi, Glass L., Dawson T.R., Wente S.R. An amyotrophic lateral sclerosis-linked mutation in GLE1 alters the cellular pool of human Gle1 functional isoforms. Adv. Biol. Regul. 2016;62:25&#x2013;36. doi: 10.1016/j.jbior.2015.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbior.2015.11.001</ArticleId><ArticleId IdType="pmc">PMC4864155</ArticleId><ArticleId IdType="pubmed">26776475</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman M.S., Mackenzie I.R., Cairns N.J., Swanson E., Boyer P.J., Drachman D.A., Jhaveri B.S., Karlawish J.H., Pestronk A., Smith T.W., et al. Novel Ubiquitin Neuropathology in Frontotemporal Dementia With Valosin-Containing Protein Gene Mutations. J. Neuropathol. Exp. Neurol. 2006;65:571&#x2013;581. doi: 10.1097/00005072-200606000-00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005072-200606000-00005</ArticleId><ArticleId IdType="pubmed">16783167</ArticleId></ArticleIdList></Reference><Reference><Citation>Borghero G., Pugliatti M., Marrosu F., Marrosu M.G., Murru M.R., Floris G., Cannas A., Occhineri P., Cau T.B., Loi D., et al. TBK1 is associated with ALS and ALS-FTD in Sardinian patients. Neurobiol. Aging. 2016;43:180. doi: 10.1016/j.neurobiolaging.2016.03.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2016.03.028</ArticleId><ArticleId IdType="pubmed">27156075</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;nch C., Sedlmeier R., Meyer T., Homberg V., Sperfeld A.D., Kurt A., Prudlo J., Peraus G., Hanemann C.O., Stumm G., et al. Point mutations of the p150 subunit of dynactin (DCTN1) gene in ALS. Neurology. 2004;63:724. doi: 10.1212/01.WNL.0000134608.83927.B1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000134608.83927.B1</ArticleId><ArticleId IdType="pubmed">15326253</ArticleId></ArticleIdList></Reference><Reference><Citation>Figlewicz D.A., Krizus A., Martinoli M.G., Meininger V., Dib M., Rouleau G.A., Julien J.-P. Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum. Mol. Genet. 1994;3:1757&#x2013;1761. doi: 10.1093/hmg/3.10.1757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/3.10.1757</ArticleId><ArticleId IdType="pubmed">7849698</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner D., M&#xfc;ller K., Wieland T., Weydt P., B&#xf6;hm S., Lul&#xe9; D., H&#xfc;bers A., Neuwirth C., Weber M., Borck G., et al. NEK1 mutations in familial amyotrophic lateral sclerosis. Brain. 2016;139:e28. doi: 10.1093/brain/aww033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww033</ArticleId><ArticleId IdType="pubmed">26945885</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Rheenen W., Shatunov A., Dekker A.M., McLaughlin R.L., Diekstra F.P., Pulit S.L., van der Spek R.A.A., V&#xf5;sa U., de Jong S., Robinson M.R., et al. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat. Genet. 2016;48:1043&#x2013;1048. doi: 10.1038/ng.3622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3622</ArticleId><ArticleId IdType="pmc">PMC5556360</ArticleId><ArticleId IdType="pubmed">27455348</ArticleId></ArticleIdList></Reference><Reference><Citation>Bannwarth S., Ait-El-Mkadem S., Chaussenot A., Genin E.C., Lacas-Gervais S., Fragaki K., Berg-Alonso L., Kageyama Y., Serre V., Moore D.G., et al. A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement. Brain. 2014;137:2329&#x2013;2345. doi: 10.1093/brain/awu138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu138</ArticleId><ArticleId IdType="pmc">PMC4107737</ArticleId><ArticleId IdType="pubmed">24934289</ArticleId></ArticleIdList></Reference><Reference><Citation>Deschauer M., Gaul C., Behrmann C., Prokisch H., Zierz S., Haack T.B. C19orf12 mutations in neurodegeneration with brain iron accumulation mimicking juvenile amyotrophic lateral sclerosis. J. Neurol. 2012;259:2434&#x2013;2439. doi: 10.1007/s00415-012-6521-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-012-6521-7</ArticleId><ArticleId IdType="pubmed">22584950</ArticleId></ArticleIdList></Reference><Reference><Citation>Geevasinga N., Menon P., Ng K., Van Den Bos M., Byth K., Kiernan M.C., Vucic S. Riluzole exerts transient modulating effects on cortical and axonal hyperexcitability in ALS. Amyotroph Lateral Scler Front. Degener. 2016;17:580&#x2013;588. doi: 10.1080/21678421.2016.1188961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1188961</ArticleId><ArticleId IdType="pubmed">27249331</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H., Mavel S., Corcia P., Gordon P.H. The glutamate hypothesis in ALS: Pathophysiology and drug development. Curr. Med. Chem. 2014;21:3551&#x2013;3575. doi: 10.2174/0929867321666140916120118.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867321666140916120118</ArticleId><ArticleId IdType="pubmed">25245510</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu H., Smith K., Camelo S.I., Carreras I., Lee J., Iglesias A.H., Dangond F., Cormier K.A., Cudkowicz M.E., Brown R.H., Jr., et al. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J. Neurochem. 2005;93:1087&#x2013;1098. doi: 10.1111/j.1471-4159.2005.03077.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2005.03077.x</ArticleId><ArticleId IdType="pubmed">15934930</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J., Ryu H., Keum G., Yoon Y.J., Kowall N.W., Ryu H. Therapeutic Targeting of Epigenetic Components in Amyotrophic Lateral Sclerosis (ALS) Curr. Med. Chem. 2014;21:3576&#x2013;3582. doi: 10.2174/0929867321666140706131825.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867321666140706131825</ArticleId><ArticleId IdType="pubmed">25005187</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J., Ryu H. Epigenetic modification is linked to Alzheimer&#x2019;s disease: Is it a maker or a marker? BMB Rep. 2010;43:649&#x2013;655. doi: 10.5483/BMBRep.2010.43.10.649.</Citation><ArticleIdList><ArticleId IdType="doi">10.5483/BMBRep.2010.43.10.649</ArticleId><ArticleId IdType="pubmed">21034526</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J., Hwang Y.J., Kim K.Y., Kowall N.W., Ryu H. Epigenetic mechanisms of neurodegeneration in Huntington&#x2019;s disease. Neurotherapeutics. 2013;10:664&#x2013;676. doi: 10.1007/s13311-013-0206-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-013-0206-5</ArticleId><ArticleId IdType="pmc">PMC3805871</ArticleId><ArticleId IdType="pubmed">24006238</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>